Company intelligence
Braveheart Bio is a clinical-stage biotech developing an oral cardiac myosin inhibitor (BHB-1893) for hypertrophic cardiomyopathy; it went public on Nasdaq in August 2026, less than a year after launching with a $185M Series A.
Is this your company? Get featured or correct your listing →
Braveheart Bio is a biotech company, based in San Francisco, California, USA, founded 2025 by Travis Murdoch. Market cap ~$1.7B-$2.2B (Sept 2026; sources vary) (As of Sep 2026, Value Add Pulse research). Total funding $185M Series A + $382.5M IPO (As of Aug 6, 2026).
| Date | Round | Amount | Valuation | Lead investors | Source |
|---|---|---|---|---|---|
| Nov 5, 2025 | Series A | $185M | — | — | PR Newswire |
Equity only. “Equity raised” above sums the rounds with a dated, linked source; rumored rounds, tender offers and secondary sales are listed but not counted, and debt financing is listed separately.
| Date | Event | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| Aug 6, 2026 | IPO | $382.5M | ~$1.27B initial pricing | BioPharma Dive |
BlossomHill and Latigo Biotherapeutics both closed upsized IPOs by August 10, capping a four-deal stretch that also included Braveheart Bio and Attovia Therapeutics pricing above or near the top of their ranges.
BlossomHill and Braveheart Bio both upsized and priced above their original ranges this week, the clearest two-deal signal yet that the biotech IPO window -- closed to all but the strongest names in 2024-2025 -- is reopening.
Braveheart Bio priced its IPO at $18 a share, above range, raising $382.5M for a cardiovascular drug licensed from China's Hengrui Pharmaceuticals -- a sign the biotech IPO window is reopening after two rough years.
Braveheart Bio priced 18.75M shares at $16 to raise $300M on Nasdaq, funding its lead drug BHB-1893 for hypertrophic cardiomyopathy in the same week two other biotechs also priced.
Braveheart Bio and Attovia Therapeutics both filed S-1s the same week, adding two names to 2026's biotech IPO pipeline amid the strongest H1 biotech venture funding since 2022.
Braveheart Bio was founded in 2025 and is headquartered in San Francisco, California, USA, according to PR Newswire and Braveheart Bio.
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.
